Clinical Characteristics and Risk Factors for Culture-Negative Periprosthetic Joint Infections

Shintaro Watanabe  
Yokohama City University: Yokohama Shiritsu Daigaku

Naomi Kobayashi  (naomik58@aol.com)  
Yokohama City Medical Center  https://orcid.org/0000-0002-2419-0860

Akito Tomoyama  
Yokohama City University: Yokohama Shiritsu Daigaku

Hyonmin Choe  
Yokohama City University: Yokohama Shiritsu Daigaku

Etsuko Yamazaki  
Yokohama City University: Yokohama Shiritsu Daigaku

Yutaka Inaba  
Yokohama City University: Yokohama Shiritsu Daigaku

Research article

Keywords: periprosthetic joint infection, culture-negative periprosthetic joint infection, antibacterial administration, inflammatory markers

DOI: https://doi.org/10.21203/rs.3.rs-67752/v2

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

**Background:** Culture-negative periprosthetic joint infections (PJIs) can complicate diagnosis and management of PJI. This study aimed to identify risk factors for culture-negative PJI and differences in clinical characteristics between culture-positive and culture-negative PJI group.

**Methods:** This retrospective, cross-sectional study evaluated PJI cases obtained between January 2013 and October 2019 at our institution. These PJI cases were divided into culture-positive and culture-negative groups and then compared. The demographics, laboratory findings, and details of patient's clinical characteristics were investigated. Univariate and multivariate logistic regression analysis were performed to investigate risk factors for culture-negative PJI.

**Results:** A total of 109 PJI cases were included in the analysis: 82 (75%) culture-positive and 27 (25%) culture-negative. The mean serum white blood cell (WBC) count, C-reactive protein level, erythrocyte sedimentation rate in the culture-negative group were significantly lower than those in the culture-positive group (p < 0.05). There were no significant differences between the two groups regarding history of prior antibacterial administration or treatment success rates. Multivariate analysis identified a lower serum WBC count as a risk factor for culture-negative PJI (odds ratio = 0.78; 95% confidence interval [CI] = 0.63–0.97; p = 0.027).

**Conclusions:** A lower serum WBC count is a risk factor for culture-negative PJI, but prior antimicrobial therapy is not. The results suggest that PJI cases with lower levels of systemic inflammation are likely to be culture-negative; therefore, the possibility of a culture-negative result should be considered in suspected cases of PJI with low inflammatory markers, regardless of prior antibiotic exposure.

Background

Periprosthetic joint infection (PJI), one of the most serious complications of joint arthroplasty, occurs in 0.8–1.9% of knee arthroplasties and in 0.3–1.7% of hip arthroplasties [1]. Diagnosis of PJI depends on various factors such as bacterial culture, clinical findings, serum laboratory data, and synovial fluid examination [2]. Early and accurate diagnosis of infection is essential to enable appropriate treatment, guided by internationally-recognized diagnostic criteria [3]. Identification of the infecting organism is particularly crucial for appropriate treatment; this includes antibiotic therapy based on the results of drug susceptibility tests and choosing surgical treatment [4, 5]. However, many cases of culture-negative PJI are encountered in a clinical setting; indeed, they account for 7–42.1% of PJI cases [6-9]. In the absence of culture results and evaluation of antibiotic sensitivity, selecting an appropriate antibiotic therapy or treatment strategy occurs without direct evidence of the responsible pathogens; therefore, culture-negative PJI is a significant clinical issue.

Studies report that culture-negative PJI is caused by several factors, including prior administration of antibiotics before obtaining culture samples, a biofilm around the implant, and culture conditions (e.g., culture medium or incubation time) [10]. In particular, the prior use of antimicrobials is likely to contribute...
to culture-negative PJI [7, 8, 11, 12]; however, the other risk factors for culture-negative PJI are unclear. In addition, few studies report the clinical characteristics of culture-negative PJI cases compared with culture-positive cases.

The clinical questions addressed by this study are: 1) what are the risk factors for culture-negative PJI? 2) Is there any difference of in the clinical characteristics of culture-positive and culture-negative PJI cases?

**Methods**

This retrospective, cross-sectional study evaluated 2776 sterile orthopedic samples obtained from 1393 cases at our institution between January 2013 and October 2019. Samples were collected using sterile technique from patients with high clinical suspicion of orthopedic infections, including PJI, infection around the implant, surgical site infection, septic arthritis, osteomyelitis, pyogenic spondylitis.

A total of 1234 cases (2391 samples) without a prosthetic joint were excluded from the evaluation. Of the 159 cases (385 samples) with a prosthetic joint, 109 (299 samples) were diagnosed as PJI according to the Musculoskeletal Infection Society criteria [2] and were included in the study. Of these 109 PJI cases, 82 (204 samples) were culture-positive PJI and 27 (95 samples) were culture-negative PJI. Culture-negative PJI was defined as a negative culture result for all samples (both preoperative and intraoperative). There were 27 males and 55 females in the culture-positive group and 13 males and 14 females in the culture-negative group. The mean age was 70 years (range 18-87) in the culture-positive group and 72 years (range 18-86) in the culture-negative group. The mean follow-up period for the culture-positive group was 39 months (range, 6–87) and that for the culture-negative group was 26 months (range, 6–78). The following parameters were examined when collecting a culture sample: serum white blood cell (WBC) count, C-reactive protein (CRP) level, erythrocyte sedimentation rate (ESR), D-dimer, American Society of Anesthesiologists (ASA) physical status classification, comorbidity, type of implant, type of sample, type of infection, use of antibacterial drugs within 2 weeks before collecting culture samples (not surgery), type of antibiotic, treatment methods, and treatment success rates. Type of infection was classified as early postoperative, acute hematogenous and chronic infection according to Tsukayama et al [13]. Treatment methods were divided into one-stage revision arthroplasty, two-stage revision arthroplasty, debridement antibiotics and implant retention (DAIR), resection arthroplasty, and observation. Although a standardized protocol was not used to determine treatment methods, multiple different surgeons used similar principles in determining treatment of choice. One-stage revision arthroplasty was performed when it was not culture-negative results, not infection with antibiotic-resistance organism, and there were no soft tissue problems [4, 5]. Two-stage revision arthroplasty treated with debridement of the infected joint, removal of the prosthetic components and placement of antibiotic-loaded hydroxyapatite block or cement spacer in the first stage. Antibiotics were administered for 6-12 weeks. Inflammatory markers such as ESR, CRP level, and WBC count and joint aspiration fluid were obtained. If there was no evidence of infection, revision arthroplasty was performed. Two-stage revision arthroplasty were mainly performed for chronic infections. Early postoperative and acute
hematogenous infections were mainly treated with DAIR. In cases with the patient’s general condition was poor, a resection arthroplasty or observation was chosen.

A standardized protocol for antibiotic treatment was not used, however, we used similar principles. For culture-positive PJI patients, intravenous antibiotics were administrated for 10–14 days, and then oral antibiotics were administrated with evaluation of antibiotic sensitivity. The administration period was approximately 6–12 weeks in total. For culture-negative PJI patients, antibiotics with broad spectrum activity were selected, and the administration period was approximately 6–12 weeks in total.

Treatment success was assessed using the Delphi consensus criteria: (1) infection eradication, characterized by a healed wound without fistula, drainage, or pain, and no reinfection by the same organism strain; (2) no subsequent surgical intervention for infection after reimplantation surgery; and (3) no occurrence of PJI-related mortality [14].

Culture methods

One or several samples were obtained from tissue, aspiration fluid, synovial fluid, and the drain. In most patients suspected of PJI, we obtained puncture from periprosthetic joint at first, and 3–5 tissue biopsy samples from different places were obtained in patients who underwent surgery. There are cases which puncture could not be obtained and surgery was not performed, therefore, there are cases of only puncture sample and only biopsy sample. In this study, cases which all samples obtained in one patient were culture-negative were defined as culture-negative PJI. All samples were sent to the microbiology laboratory. Standard culture was performed at first. If samples were not cultured using standard culture methods, an enrichment culture method was performed using broth culture medium for 5 days according to a previous study [15]. Briefly, standard culture was performed using 5% sheep’s blood agar plates containing peptone and sodium chloride. The enrichment culture comprised semi-solid Gifu anaerobic medium containing peptone, soy peptone, protease peptone, beef extract, yeast extract, liver extract, glucose, starch, L-tryptophan, L-cysteine hydrochloride, thioglycolic acid sodium salt, L-arginine, vitaminK1, hemin, potassium dihydrogen phosphate, and sodium chloride. The standard culture method was conducted for 24 h at 35°C/5% CO₂. Enrichment culture was performed for 5 days at 35°C in ambient air. When the enrichment culture was negative, it was identified as culture-negative. Bacteria were identified by analysis of biological properties using MicroScan WalkAway and a combo panel (Beckman Coulter, Brea, CA).

Statistical analysis

The PJI cases were divided into culture-positive and culture-negative groups. The two groups were compared using Student’s t-tests (continuous variables) or Chi-square test (categorical variables). Residual analysis was performed after Chi-square tests to observe the significance difference between groups. Risk factors for culture-negative PJI were evaluated using univariate and multivariate logistic regression analysis. Univariate logistic regression analysis was performed to identify the independent
influence of each variable in Table 1. Baseline variables with a p-value < 0.10 in univariate analysis were included in multivariate analysis. A p-value < 0.05 was considered significant.

Results

Figure 1 shows the number of cases in each culture-positive and culture-negative PJI groups. A total of 82 cases (75%) were culture-positive and 27 (25%) were culture-negative. Table 1 shows the demographic characteristics of each group. There were no significant differences in comorbidities, type of infection, and type of implant between groups (Table 1). There was no difference in the rate of prior antibiotics administration between groups (culture-positive group, 61%, 50 of 82 cases; culture-negative group, 56%, 15 of 27 cases; p = 0.62, Table 1). The treatment success rate was not significantly different between groups (culture-positive group, 88%, 72 of 82 cases; culture-negative group, 74%, 20 of 27 cases; p = 0.088, Table 1).

The mean serum WBC count, CRP level, and ESR in the culture-negative PJI group were significantly lower than those in the culture-positive PJI group (WBC: 8218 cells/μL versus 6185 cells/μL, p = 0.011; CRP: 5.0 mg/dL versus 2.5 mg/dL, p = 0.032; and ESR: 60 mm/h versus 47 mm/h, p = 0.036; respectively, Figure 2). Table 2 lists the microorganisms identified in the culture-positive group. Table 3 lists the antimicrobial drugs taken by patients in each group. In some cases, multiple antibiotics were used. Univariate analysis identified a serum WBC count (×10^3) (odds ratio = 0.80; 95% confidence interval [CI] = 0.65–0.98; p = 0.028, Table 4) as a risk factor for culture-negative PJI. Baseline variables with a p-value < 0.10 in univariate analysis were serum WBC count, CRP, and ESR; these factors included in multivariate analysis. Multivariate analysis identified a serum WBC count (×10^3) (odds ratio = 0.78; 95% CI = 0.63–0.97; p = 0.027, Table 5) as the most significant risk factor for culture-negative PJI.

Discussion

This study demonstrated that 25% of PJI cases investigated were culture-negative. There were some differences in clinical characteristics between the culture-positive and culture-negative PJI groups. Levels of systemic inflammatory markers such as serum WBC count, CRP level, and ESR in the culture-negative group were significantly lower than those in the culture-positive group. The treatment success rate of culture-negative PJI was no different from that of culture-positive PJI. A lower serum WBC count was identified as a risk factor for culture-negative PJI, but prior antimicrobial therapy was not.

In the current study, the observation that several serum inflammatory markers (all of which are important as first-line tests for diagnosis of PJI) [16] were significantly lower in the culture-negative group than those in the culture-positive group has important clinical implications. In agreement with our results, Choi et al. reported that serum ESR in culture-negative patients was lower than in culture-positive patients [7]. In addition, a previous study by Kheir et al. demonstrated that culture-negative PJI cases had lower CRP values than PJI cases caused by Gram-negative organisms, antibiotic-resistant organisms, *Staphylococcus aureus*, and *Streptococcus* species; they also had lower WBC counts than PJI cases.
caused by *Staphylococcus aureus* and *Streptococcus* species [17]. The results of our study suggest that culture-negative PJI is caused by less virulent organisms and that the organism count is lower, resulting in less severe systemic inflammation. In this regard, the ideal cut-off value for these markers may need reconsideration for more accurate screening of PJI [18].

We found that the single risk factor for culture-negative PJI was a lower serum WBC count. Although several risk factors for culture-negative PJI have been described [7, 8, 11, 12], serum WBC count was not highlighted. This result suggests that culture-negative PJI should be considered in suspected cases with low levels of inflammatory markers. In such cases, additional diagnostic approaches such as polymerase chain reaction (PCR) or alpha-defensin tests may be required [19, 20]. PCR has excellent diagnostic value for patients with PJI, with pooled sensitivity of 86% and specificity of 91% [19]. In addition, the alpha-defensin test for synovial fluid shows excellent diagnostic performance in patients with PJI [20]. Thus, molecular techniques or novel biomarkers may be an alternative diagnostic tool for culture-negative cases.

In the present study, prior use of antibiotics had no effect on culture-positive or culture-negative PJI. In addition, the multifactorial logistic regression model did not identify prior antimicrobial therapy as a risk factor for culture-negative PJI. Several studies demonstrate that perioperative administration of prophylactic antibiotics has no effect on culture yield [21-24]. Tetreault et al. reported that prophylactic antibiotics administered before skin incision had no effect on the results of cultures obtained intraoperatively [21]. A prospective study by Bedencic et al. revealed no differences in diagnostic yield between cultures taken before and after administration of antibiotics to patients with suspected PJI [22]. Thus, use of antibiotics before collecting culture samples may not affect culture results. By contrast, several studies demonstrate that prior use of antimicrobial therapy is a risk factor for culture-negative PJI [7, 11, 12]. Malekzadeh et al. reported that antimicrobial therapy before diagnosis of PJI is associated with increased odds (odds ratio, 4.7) of being culture-negative [11]. In addition, Ibrahim M. S. et al. showed that pre-operative use of antibiotics was a risk factor for culture-negative PJI (odds ratio, 4.1) [12]. A reasonable explanation for a causal association between antibiotics administration and culture-negative results is that antibiotic pressure can induce a viable but non-culturable state in a biofilm [25]. Thus, prior antibiotics use in suspected cases of PJI is a controversial issue; therefore, further studies are required.

In this study, the treatment success rate of culture-negative PJI was similar to that of culture-positive PJI. In agreement with our results, previous studies reported similar outcomes for culture-positive and culture-negative PJI patients [12, 26]. In addition, Choi et al. reported that the success rate of infection control was higher in the culture-negative group [7]. Thus, culture-negative PJI may not necessarily be a negative prognostic factor for PJI. Certainly, culture-negative PJI was associated with less virulent organisms and a lower organism count; therefore, the clinical outcome of culture-negative PJI might not be poor despite the lack of culture results and antibiotic sensitivity. On the contrary, inadequate treatment may lead to unsuccessful results for culture-negative PJI. In fact, the rate of treatment success was greater for
patients with 2-stage exchange than for those with irrigation and debridement [27]. In addition, selection of antibiotics is difficult in the absence of information about the causative organism.

This study has several limitations. First, the rate of prior antibiotics use was high: 61% and 56% in the culture-positive and -negative groups, respectively. A previous study reported a rate of prior use of antimicrobial therapy of 64% in the culture-negative group and 24% in the culture-positive group [11]. In our study, many PJI cases were referred from other hospitals, and many were had already been treated with antibiotics. In addition, antibiotic therapy after surgery was determined by multiple different surgeons, therefore, antibiotic treatment methods (type and period of administration) were not standardized. These limitations might have led to selection bias and affect our results of the influence of antibiotics. Second, our sample sizes were relatively small because PJI is a rare condition in a single center. Further multicenter studies need to be performed with more cases. Third, while 5 days culture period was applied in this study, an international consensus meeting recommended that routine cultures should be maintained for 5–14 days [28]. It is, therefore, possible that longer culture duration may have yielded different results, particularly in organisms with a low level of virulence. However, Kheir et al reported that most organisms were cultured within 5 days [29]. The current study was conducted on the assumption that most organisms would be cultured within 5 days, and that these durations would limit the risk of isolating contaminant organisms. On the other hand, we cannot deny the possibility the percentage of positive culture will slightly increase after 5 days culture. This is a kind of “trade-off” relation between time required and positive percentage: we presume that culture period with 5 days might be a reasonable balance. Fourth, molecular and modern techniques such as sonication of implants, PCR, alpha-defensin tests, and next-generation sequencing were not used in our study, therefore, the proportion of culture-negative PJI might be otherwise. Finally, there is a significant difference in follow-up period between the culture-positive group and culture-negative group. In addition, treatment methods were not standardized; this may have affected the treatment success rates. In fact, four culture-negative PJI cases were treated with one-stage revision arthroplasty, although it is considered a contraindication for culture-negative PJI [4]. These cases were diagnosed as aseptic loosening before surgery, but pathological results were positive and they were diagnosed as PJI after surgery. These were treated as PJI after surgery, the infection was eradicated.

Conclusions

We identified a single risk factor for culture-negative PJI and key differences between culture-positive PJI and culture-negative PJI patients. A lower serum WBC count was associated with culture-negative PJI, but prior antimicrobial therapy was not. A clinical characteristic associated with culture-negative PJI was low levels of inflammatory markers. There was no difference in treatment success rates between the groups. It is possible that culture-negative PJI should be considered in suspected cases of PJI with low inflammatory markers, regardless of prior antibiotics administration.

Abbreviations
PJI, periprosthetic joint infection; WBC, white blood cell; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; ASA, American Society of Anesthesiologists; DAIR, debridement antibiotics and implant retention; PCR, polymerase chain reaction; CI, confidence interval; COPD, chronic obstructive pulmonary disease; THA, total hip arthroplasty; TKA, total knee arthroplasty; TEA, total elbow arthroplasty; MRSE, methicillin-resistant *Staphylococcus epidermidis*; MRSA, methicillin-resistant *Staphylococcus aureus*; ESBL, extended-spectrum beta-lactamase; MRS, methicillin-resistant *Staphylococcus*.

**Declarations**

**Ethics approval and consent to participate**

Ethical approval for this study was obtained from the institutional review board of Yokohama City University ethical committee (number B180900011). Informed and written consent was obtained from all patients.

**Consent for publication**

Not applicable.

**Availability of date and materials**

The datasets used and/or analyzed during the current study are available from the corresponding author or reasonable request.

**Competing interests**

The authors declare that they have no competing interests.

**Funding**

No funding was obtained for this study.

**Authors’ contributions**

SW: study design, date collection, and writing the paper. NK: study design, critical revision. AT: date analysis and interpretation. HC: date analysis and interpretation. EY: date analysis and interpretation. YI: study design, critical revision. All authors read and approved the final manuscript.

**Acknowledgements**

Not applicable.

**Conflict of interest**

The authors declare no conflicts of interest.
References

1. Del Pozo JL, Patel R: **Clinical practice. Infection associated with prosthetic joints.** *The New England journal of medicine* 2009, 361(8):787-794.

2. Shohat N, Bauer T, Buttaro M, Budhiparama N, Cashman J, Della Valle CJ, Drago L, Gehrke T, Marcelino Gomes LS, Goswami K *et al.*: *Hip and Knee Section, What is the Definition of a Periprosthetic Joint Infection (PJI) of the Knee and the Hip? Can the Same Criteria be Used for Both Joints?: Proceedings of International Consensus on Orthopedic Infections.* *J Arthroplasty* 2019, 34(2s):S325-s327.

3. Parvizi J, Tan TL, Goswami K, Higuera C, Della Valle C, Chen AF, Shohat N: **The 2018 Definition of Periprosthetic Hip and Knee Infection: An Evidence-Based and Validated Criteria.** *J Arthroplasty* 2018, 33(5):1309-1314.e1302.

4. Negus JJ, Gifford PB, Haddad FS: **Single-Stage Revision Arthroplasty for Infection-An Underutilized Treatment Strategy.** *J Arthroplasty* 2017, 32(7):2051-2055.

5. Haddad FS, Masri BA, Garbuz DS, Duncan CP: **The treatment of the infected hip replacement. The complex case.** *Clinical orthopaedics and related research* 1999(369):144-156.

6. Berbari EF, Marculescu C, Sia I, Lahr BD, Hanssen AD, Steckelberg JM, Gullerud R, Osmon DR: **Culture-negative prosthetic joint infection.** *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America* 2007, 45(9):1113-1119.

7. Choi HR, Kwon YM, Freiberg AA, Nelson SB, Malchau H: **Periprosthetic joint infection with negative culture results: clinical characteristics and treatment outcome.** *J Arthroplasty* 2013, 28(6):899-903.

8. Kim YH, Kulkarni SS, Park JW, Kim JS, Oh HK, Rastogi D: **Comparison of infection control rates and clinical outcomes in culture-positive and culture-negative infected total-knee arthroplasty.** *Journal of orthopaedics* 2015, 12(Suppl 1):S37-43.

9. Kim YH, Park JW, Kim JS, Kim DJ: **The outcome of infected total knee arthroplasty: culture-positive versus culture-negative.** *Arch Orthop Trauma Surg* 2015, 135(10):1459-1467.

10. Parvizi J, Erkocak OF, Della Valle CJ: **Culture-negative periprosthetic joint infection.** *The Journal of bone and joint surgery American volume* 2014, 96(5):430-436.

11. Malekzadeh D, Osmon DR, Lahr BD, Hanssen AD, Berbari EF: **Prior use of antimicrobial therapy is a risk factor for culture-negative prosthetic joint infection.** *Clinical orthopaedics and related research* 2010, 468(8):2039-2045.

12. Ibrahim MS, Twaij H, Haddad FS: **Two-stage revision for the culture-negative infected total hip arthroplasty: A comparative study.** *The bone & joint journal* 2018, 100-b(1 Supple A):3-8.

13. Tsukayama DT, Estrada R, Gustilo RB: **Infection after total hip arthroplasty. A study of the treatment of one hundred and six infections.** *The Journal of bone and joint surgery American volume* 1996, 78(4):512-523.

14. Diaz-Ledezma C, Higuera CA, Parvizi J: **Success after treatment of periprosthetic joint infection: a Delphi-based international multidisciplinary consensus.** *Clinical orthopaedics and related research*
2013, 471(7):2374-2382.

15. Watanabe S, Kobayashi N, Tomoyama A, Choe H, Yamazaki E, Inaba Y: Differences in Diagnostic Properties Between Standard and Enrichment Culture Techniques Used in Periprosthetic Joint Infections. J Arthroplasty 2020, 35(1):235-240.

16. Greidanus NV, Masri BA, Garbuz DS, Wilson SD, McAlinden MG, Xu M, Duncan CP: Use of erythrocyte sedimentation rate and C-reactive protein level to diagnose infection before revision total knee arthroplasty. A prospective evaluation. The Journal of bone and joint surgery American volume 2007, 89(7):1409-1416.

17. Kheir MM, Tan TL, Shohat N, Foltz C, Parvizi J: Routine Diagnostic Tests for Periprosthetic Joint Infection Demonstrate a High False-Negative Rate and Are Influenced by the Infecting Organism. The Journal of bone and joint surgery American volume 2018, 100(23):2057-2065.

18. Bingham JS, Hassebrock JD, Christensen AL, Beauchamp CP, Clarke HD, Spangehl MJ: Screening for Periprosthetic Joint Infections With ESR and CRP: The Ideal Cutoffs. J Arthroplasty 2019.

19. Qu X, Zhai Z, Li H, Li H, Liu X, Zhu Z, Wang Y, Liu G, Dai K: PCR-based diagnosis of prosthetic joint infection. Journal of clinical microbiology 2013, 51(8):2742-2746.

20. Berger P, Van Cauter M, Driesen R, Neyt J, Cornu O, Bellemans J: Diagnosis of prosthetic joint infection with alpha-defensin using a lateral flow device: a multicentre study. The bone & joint journal 2017, 99-b(9):1176-1182.

21. Tetreault MW, Wetters NG, Aggarwal V, Mont M, Parvizi J, Della Valle CJ: The Chitranjan Ranawat Award: Should prophylactic antibiotics be withheld before revision surgery to obtain appropriate cultures? Clinical orthopaedics and related research 2014, 472(1):52-56.

22. Bedencic K, Kavcic M, Faganeli N, Mihalic R, Mavcic B, Dolenc J, Bajc Z, Trebse R: Does Preoperative Antimicrobial Prophylaxis Influence the Diagnostic Potential of Periprosthetic Tissues in Hip or Knee Infections? Clinical orthopaedics and related research 2016, 474(1):258-264.

23. Wouthuyzen-Bakker M, Tomero E, Claret G, Bosch J, Martinez-Pastor JC, Combalia A, Soriano A: Withholding Preoperative Antibiotic Prophylaxis in Knee Prosthesis Revision: A Retrospective Analysis on Culture Results and Risk of Infection. J Arthroplasty 2017, 32(9):2829-2833.

24. Burnett RS, Aggarwal A, Givens SA, McClure JT, Morgan PM, Barrack RL: Prophylactic antibiotics do not affect cultures in the treatment of an infected TKA: a prospective trial. Clinical orthopaedics and related research 2010, 468(1):127-134.

25. Pasquaroli S, Zandi G, Vignaroli C, Vuotto C, Donelli G, Biavasco F: Antibiotic pressure can induce the viable but non-culturable state in Staphylococcus aureus growing in biofilms. The Journal of antimicrobial chemotherapy 2013, 68(8):1812-1817.

26. Wang J, Wang Q, Shen H, Zhang X: Comparable outcome of culture-negative and culture-positive periprosthetic hip joint infection for patients undergoing two-stage revision. International orthopaedics 2018, 42(3):469-477.

27. Tan TL, Kheir MM, Shohat N, Tan DD, Kheir M, Chen C, Parvizi J: Culture-Negative Periprosthetic Joint Infection: An Update on What to Expect. JB & JS open access 2018, 3(3):e0060.
28. Zmistowski B, Della Valle C, Bauer TW, Malizos KN, Alavi A, Bedair H, Booth RE, Choong P, Deirmengian C, Ehrlich GD et al: Diagnosis of periprosthetic joint infection. J Arthroplasty 2014, 29(2 Suppl):77-83.

29. Kheir MM, Tan TL, Ackerman CT, Modi R, Foltz C, Parvizi J: Culturing Periprosthetic Joint Infection: Number of Samples, Growth Duration, and Organisms. J Arthroplasty 2018.

Tables

Table 1. Characteristics of culture-positive and culture-negative patients
| Characteristics                          | Culture-positive | Culture-negative | P-value |
|-----------------------------------------|------------------|------------------|---------|
| Cases (%) (Samples)                     | 82 (75%) (204)   | 27 (25%) (95)    |         |
| Median age (range)                      | 70 years (18–87) | 72 years (18–86) | 0.17    |
| Gender                                  | 27 male/55 female | 13 male/14 female | 0.15    |
| Comorbidity                             |                  |                  |         |
| Hypertension                            | 32 (39%)         | 11 (41%)         | 0.88    |
| Diabetes mellitus                       | 11 (13%)         | 6 (22%)          | 0.27    |
| Renal insufficiency                     | 7 (8.5%)         | 4 (15%)          | 0.35    |
| Liver cirrhosis                         | 8 (9.8%)         | 3 (11%)          | 0.84    |
| Cardiovascular disease                  | 12 (15%)         | 3 (11%)          | 0.64    |
| COPD                                    | 3 (3.7%)         | 1 (3.7%)         | 0.99    |
| Rheumatoid arthritis                    | 5 (6.1%)         | 4 (15%)          | 0.15    |
| Mean follow-up (months)                 | 39 (6–87)        | 26 (6–78)        | 0.015   |
| Mean ASA physical status                | 2.06             | 2                | 0.23    |
| Type of infection                       |                  |                  | 0.15    |
| Early postoperative                     | 7 (8.5%)         | 6 (22%)          |         |
| Acute hematogenous                      | 15 (18%)         | 5 (19%)          |         |
| Chronic                                 | 60 (73%)         | 16 (59%)         |         |
| Type of implant                         |                  |                  | 0.51    |
| THA                                     | 49 (60%)         | 12 (44%)         |         |
| Hip hemi-arthroplasty                   | 6 (7.3%)         | 5 (19%)          |         |
| Hip megaprosthesis                      | 5 (6.1%)         | 2 (7.4%)         |         |
| TKA                                     | 11 (13%)         | 6 (22%)          |         |
| Knee megaprosthesis                     | 6 (7.3%)         | 1 (3.7%)         |         |
| Shoulder hemi-arthroplasty              | 4 (4.9%)         | 1 (3.7%)         |         |
| Type of samples          | 1 (1.2%) | 0 (0%) | 0.072 |
|-------------------------|----------|--------|-------|
| Tissue                  | 142 (70%)| 62 (65%)|       |
| Fluid sample            | 60 (29%) | 28 (29%)|       |
| Drain                   | 2 (1.0%) | 5 (5.3%)|       |
| Prior antimicrobial administration | 50 (61%) | 15 (56%) | 0.62 |
| Yes                     | 32 (39%) | 12 (44%)|       |
| No                      |          |        |       |
| Treatment               |          |        | 0.044 |
| One-stage               | 6 (7.3%) | 4 (15%) |       |
| Two-stage               | 54 (66%) | 12 (44%)|       |
| DAIR                    | 14 (17%) | 7 (26%) |       |
| Resection arthroplasty  | 8 (10%)  | 2 (7.4%)|       |
| Observation             | 0 (0%)   | 2 (7.4%)|       |
| Treatment success       |          |        | 0.088 |
| Yes                     | 72 (88%) | 20 (74%)|       |
| No                      | 10 (12%) | 1 (26%) |       |

P-value < 0.05

COPD, chronic obstructive pulmonary disease; ASA, American Society of Anesthesiologists; THA, total hip arthroplasty; TKA, total knee arthroplasty; TEA, total elbow arthroplasty; DAIR, debridement antibiotics and implant retention.

**Table 2.** Organisms identified in the culture-positive group
| Organisms                                         | Culture-positive |
|--------------------------------------------------|------------------|
| *Staphylococcus epidermidis* (MRSE)               | 16 (20%)         |
| *Staphylococcus aureus*                          | 7 (8.5%)         |
| *Staphylococcus aureus* (MRSA)                   | 7 (8.5%)         |
| Corynebacterium sp.                              | 5 (6.1%)         |
| *Escherichia coli*                               | 5 (6.1%)         |
| *Candida albicans*                               | 4 (4.9%)         |
| *Peptostreptococcus species*                     | 4 (4.9%)         |
| *Pseudomonas aeruginosa*                         | 4 (4.9%)         |
| *Enterococcus faecalis*                          | 3 (3.7%)         |
| *Escherichia coli* (ESBL)                        | 3 (3.7%)         |
| Non-hemolytic *Streptococcus*                    | 3 (3.7%)         |
| *Staphylococcus capitis-capit* (MRS)             | 3 (3.7%)         |
| *Staphylococcus lugdunensis*                     | 3 (3.7%)         |
| *Staphylococcus auricularis*                     | 2 (2.4%)         |
| *Staphylococcus species* (coagulase-negative)    | 2 (2.4%)         |
| *Streptococcus agalactiae*                       | 2 (2.4%)         |
| *Streptococcus anginosus*                        | 2 (2.4%)         |
| Aerobic Gram-positive bacillus                   | 1 (1.2%)         |
| Corynebacterium striatum                         | 1 (1.2%)         |
| Micrococcus species                              | 1 (1.2%)         |
| Nonfermenting Gram-negative bacillus             | 1 (1.2%)         |
| *Staphylococcus auricularis* (MRS)               | 1 (1.2%)         |
| *Staphylococcus caprae*                          | 1 (1.2%)         |
| *Staphylococcus lugdunensis* (MRS)               | 1 (1.2%)         |
| **Total**                                        | **82**           |

MRSE, methicillin-resistant *Staphylococcus epidermidis*; MRSA, methicillin-resistant *Staphylococcus aureus*; ESBL, extended-spectrum beta-lactamase; MRS, methicillin-
resistant *Staphylococcus*.

**Table 3.** Type of antimicrobial therapy administered to patients in each group

| Type of antimicrobial          | Culture-positive | Culture-negative |
|-------------------------------|------------------|------------------|
| amoxicillin                   | 1 (1.1%)         | 0 (0%)           |
| ceftazidime                   | 0 (0%)           | 1 (4.0%)         |
| cefaclor                      | 5 (5.2%)         | 0 (0%)           |
| cefazolin                     | 14 (15%)         | 2 (8.0%)         |
| cefepime                      | 0 (0%)           | 1 (4.0%)         |
| cefcapene pivoxil             | 2 (2.1%)         | 1 (4.0%)         |
| clindamucin                   | 8 (8.4%)         | 3 (12%)          |
| ciprofloxacin                 | 1 (1.1%)         | 0 (0%)           |
| ceftriaxone                   | 0 (0%)           | 1 (4.0%)         |
| daptomycin                    | 2 (2.1%)         | 2 (8.0%)         |
| doripenem                     | 2 (2.1%)         | 1 (4.0%)         |
| levofloxacin                  | 18 (19%)         | 3 (12%)          |
| meropenem                     | 1 (1.1%)         | 1 (4.0%)         |
| minocycline                   | 15 (16%)         | 0 (0%)           |
| penicillin G                  | 0 (0%)           | 1 (4.0%)         |
| rifampicin                    | 17 (18%)         | 6 (24%)          |
| sulfamethoxazole-trimethoprim| 5 (5.2%)         | 0 (0%)           |
| tazobactam/piperacillin       | 3 (3.2%)         | 1 (4.0%)         |
| vancomycin                    | 1 (1.1%)         | 1 (4.0%)         |
| **Total**                     | **95**           | **25**           |

**Table 4.** Univariate analysis of risk factors for culture-negative periprosthetic joint infection
| Variable                        | Odds ratio | 95% confidence interval | P-value |
|--------------------------------|------------|-------------------------|---------|
| Age                            | 1.01       | 0.99–1.05               | 0.33    |
| Gender (female)                | 0.53       | 0.22–1.28               | 0.16    |
| **Comorbidity**                |            |                         |         |
| Hypertension                   | 1.07       | 0.44–2.61               | 0.87    |
| Diabetes mellitus              | 1.84       | 0.61–5.58               | 0.28    |
| Renal insufficiency            | 1.86       | 0.50–6.94               | 0.35    |
| Liver cirrhosis                | 1.16       | 0.28–4.71               | 0.84    |
| Cardiovascular disease         | 0.73       | 0.19–2.81               | 0.65    |
| COPD                           | 1.01       | 0.10–10.2               | 0.99    |
| Rheumatoid arthritis           | 2.68       | 0.66–10.8               | 0.17    |
| ASA physical status            | 0.63       | 0.18–2.14               | 0.46    |
| Type of infection (Chronic)    | 0.53       | 0.21–1.32               | 0.18    |
| Prior antimicrobial therapy    | 0.80       | 0.33–1.93               | 0.62    |
| Serum WBC (×10³)               | 0.80       | 0.65–0.98               | 0.028†  |
| CRP                            | 0.89       | 0.77–1.02               | 0.087   |
| ESR                            | 0.99       | 0.97–1.00               | 0.075   |
| D-dimer                        | 1.05       | 0.88–1.25               | 0.60    |
| Fluid sample                   | 0.82       | 0.49–1.38               | 0.45    |

[†] P-value < 0.05

COPD, chronic obstructive pulmonary disease; ASA, American Society of Anesthesiologists; WBC, white blood cell; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate.

**Table 5.** Multivariable analysis of risk factors for culture-negative periprosthetic joint infection

| Variable                  | Odds ratio | 95% confidence interval | P-value |
|---------------------------|------------|-------------------------|---------|
| Serum WBC (×10³)          | 0.78       | 0.63–0.97               | 0.027†  |
| ESR                       | 0.98       | 0.97–1.00               | 0.053   |
P-value < 0.05

Factors with a p-value < 0.10 in univariate were included in the multivariate model. WBC, white blood cell; ESR, erythrocyte sedimentation rate.